Biochimie, Journal Year: 2020, Volume and Issue: 179, P. 266 - 274
Published: Sept. 3, 2020
Language: Английский
Infection Genetics and Evolution, Journal Year: 2020, Volume and Issue: 87, P. 104647 - 104647
Published: Nov. 29, 2020
Language: Английский
Citations
75
Hepatology, Journal Year: 2022, Volume and Issue: 76(6), P. 1563 - 1575
Published: May 21, 2022
Abstract Background and Aims Cholestasis is associated with disease severity worse outcome in COVID‐19. Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection have been described. Approach Results Hospitalized patients COVID‐19 between 03/2020 07/2021 were included. Patients stratified as having (i) no chronic liver (CLD), (ii) non‐advanced CLD (non‐ACLD), or (iii) advanced (ACLD). non–COVID‐19 pneumonia matched to a control cohort. Liver chemistries before (Pre) at first, second, third blood withdrawal SARS‐CoV‐2 (T1–T3) last available time point (last) recorded. A total 496 In total, 13.1% ( n = 65) had (non‐ACLD: 70.8%; ACLD: 29.2%); the predominant etiology was NAFLD/NASH (60.0%). COVID‐19–related injury more common among (24.6% vs. 10.6%; p 0.001). After infection, exhibited progressive cholestasis persistently increasing levels alkaline phosphatase (Pre: 91.0 T1: 121.0 last: 175.0 U/L; < 0.001) gamma‐glutamyl transferase 95.0 135.0 202.0 23.1% 15/65) developed cholestatic failure (cholestasis plus bilirubin ≥6 mg/dl) during COVID‐19, 15.4% 10/65) SSC. SSC significantly frequent than 0.040). COVID‐19–associated occurred predominantly metabolic risk factors. 26.3% 5/19) ACLD experienced hepatic decompensation infection. Conclusions About 20% develop factors are particular for developing and/or
Language: Английский
Citations
65
Internal and Emergency Medicine, Journal Year: 2021, Volume and Issue: 16(6), P. 1487 - 1496
Published: Jan. 5, 2021
The factors that predispose an individual to a higher risk of death from COVID-19 are poorly understood. goal the study was identify associated with among patients COVID-19. This is retrospective cohort people laboratory-confirmed SARS-CoV-2 infection February May 22, 2020. Data retrieved for this included patient sociodemographic data, baseline comorbidities, treatments, other background data on care provided in hospital or primary settings, and vital status. Main outcome deaths until June 29, In multivariable model based nursing home residents, predictors mortality were being male, older than 80 years, admitted COVID-19, having cardiovascular disease, kidney disease dementia while taking anticoagulants lipid-lowering drugs at protective. AUC 0.754 score 0.717 validation subsample. Predictors general population male and/or 60 been hospitalized month before admission dementia, respiratory liver diabetes organ damage, cancer 0.941 model's 0.938 Our scores could help physicians high-risk groups establish preventive measures better follow-up high dying.ClinicalTrials.gov Identifier: NCT04463706.
Language: Английский
Citations
57
Hepatology Communications, Journal Year: 2021, Volume and Issue: 6(2), P. 255 - 269
Published: Oct. 20, 2021
Liver injury, characterized predominantly by elevated aspartate aminotransferase and alanine aminotransferase, is a common feature of coronavirus disease 2019 (COVID-19) symptoms caused severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Additionally, SARS-CoV-2 infection associated with acute-on-chronic liver failure in patients cirrhosis has notably mortality alcohol-related compared to other etiologies. Direct viral the remains controversial, alternative pathophysiologic explanations for its hepatic effects are an area active investigation. In this review, we discuss inflammatory environment it creates on endothelial cells platelets more generally then focus. doing this, present vascular inflammation thrombosis as potential mechanism injury liver-related complications COVID-19.
Language: Английский
Citations
57
Frontiers in Medicine, Journal Year: 2020, Volume and Issue: 7
Published: July 21, 2020
The COVID-19 outbreak is a great threat to public health worldwide. Lung injury the main outcome of infection; however, damage can occur in other organs including liver. Currently, limited data are available that link underlying liver with severe SARS-CoV-2 infection. This review summarizes on test abnormalities patients; critically evaluates possible causes and provides recommendations for clinicians. In laboratory tests, serum levels markers notably transaminase, gamma-glutamyl transferase total bilirubin were significantly higher patients use certain drugs especially lopinavir ritonavir showed an association progression cases. Available suggest may result from direct effect by virus, immune-mediated inflammation or drug-induced toxicity. Some studies demonstrated pre-existing disease at risk hospitalizations mortality. Therefore, impact treatment clinical outcomes should be determined. Large-scale needed identify
Language: Английский
Citations
70
European Journal of Clinical Investigation, Journal Year: 2020, Volume and Issue: 51(1)
Published: Oct. 12, 2020
Increased concentrations of serum aspartate transaminase (AST) and alanine (ALT) are common in COVID-19 patients. However, their capacity to predict mortality, particularly the AST/ALT ratio, commonly referred as De Ritis is unknown. We investigated association between ratio on admission in-hospital mortality 105 consecutive patients with coronavirus disease 2019 (COVID-19) admitted three referral centres Sardinia, Italy. The was significantly lower survivors than nonsurvivors (median: 1.25; IQR: 0.91-1.64 vs 1.67; 1.38-1.97, P = .002) whilst there were no significant between-group differences ALT AST concentrations. In ROC curve analysis, AUC value 0.701 (95% CI 0.603-0.787, .0006) sensitivity specificity 74% 70%, respectively. Kaplan-Meier survival curves showed a (logrank test .014). By contrast, associations observed .83 .62, respectively). multivariate Cox regression HR ratios ≥1.63 (upper tertile this parameter) remained after adjusting for age, gender, smoking status, cardiovascular disease, intensity care, diabetes, respiratory diseases, malignancies kidney (HR: 2.46, 95% 1.05-5.73, .037). Therefore, associated Larger studies required confirm parameter independently group.
Language: Английский
Citations
67
Expert Review of Gastroenterology & Hepatology, Journal Year: 2020, Volume and Issue: 14(10), P. 879 - 884
Published: July 10, 2020
Introduction The outbreak of COVID-19 is a serious health threat worldwide. Different degrees liver injury or dysfunctions have been reported in patients with infection. However, currently, it remains unclear to what extent diseases should be considered as significant risk factors for the severity and mortality COVID-19. Moreover, mechanisms involved severe infection are not yet well understood.
Language: Английский
Citations
62
Journal of Gastroenterology, Journal Year: 2021, Volume and Issue: 56(3), P. 218 - 230
Published: Feb. 1, 2021
Language: Английский
Citations
49
International Journal of Clinical Practice, Journal Year: 2022, Volume and Issue: 2022, P. 1 - 24
Published: Oct. 31, 2022
It is considered that COVID-19’s pandemic expansion responsible for the particular increase in deaths, especially among population with comorbidities. The health system often overwhelmed by large number of cases patients addressing it, regional limitation funds, and gravity at subjects suffering from this pathology. Several associated conditions including diabetes, cardiovascular illnesses, obesity, persistent lung condition, neurodegenerative diseases, etc., mortality risk hospitalization COVID-19. rapid identification increased death SARS-CoV-2 virus, stratification accordance allocation human, financial, logistical resources proportion must be a priority systems worldwide.
Language: Английский
Citations
36
World Journal of Clinical Cases, Journal Year: 2022, Volume and Issue: 10(4), P. 1140 - 1163
Published: Jan. 18, 2022
Coronavirus disease 2019 (COVID-19) has caused a pandemic that affected all countries with nearly 270 million patients and 5 deaths, as of December, 2021. The severe acute respiratory syndrome coronavirus 2 virus targets the receptor, angiotensin-converting enzyme 2, which is frequently found in human intestinal epithelial cells, bile duct liver gastrointestinal system organs are by COVID-19 infection. aim this study to review manifestations damage infection investigate risk have chronic disease, along current treatment guidelines. A literature search was conducted on electronic databases PubMed, Scopus, Cochran Library, consisting COVID-19, injury, findings, treatment. Liver involvements most common manifestations. Diarrhea, anorexia, nausea/vomiting, abdominal pain frequent symptoms seen involvement. Mild hepatitis occurs elevated levels transaminases. Gastrointestinal involvement associated long hospital stay, severity intensive care unit necessity. Treatments follow-up inflammatory bowel diseases, cirrhosis, hepatocellular carcinoma, or transplant been negatively during pandemic. Patients auto-immune transplantation may greater for COVID-19. Diagnostic therapeutic procedures should be restricted specific conditions. Telemedicine used non-urgent periodic patient follow up. not delayed at group. vaccination prioritized
Language: Английский
Citations
31